MDS cannot be categorized as a suspected disease in the field of blood tumours, clinical performance is complex and often involves multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of MDS requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can help align teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of MDS cannot be categorized as a multi-dimensional treatment program, usually including drug therapy, rehabilitation interventions, regular follow-up, etc. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved.
Treatment needs to closely monitor efficacy and adverse reactions, adapting timely to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of MDS that cannot be categorized. The platform serves a team of domestically and internationally authoritative experts in the field of blood oncology in China.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.